Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Down 88%, Could Editas Medicine Be a Good Investment Now?
05:19am, Monday, 15'th Jan 2024
Editas Medicine is a clinical-stage drugmaker developing CRISPR-based gene therapies. So far, Editas Medicine's candidate for sickle cell disease patients is performing well in clinical trials.
3 Stocks to Buy in the Booming Field of Gene Editing
04:38pm, Thursday, 11'th Jan 2024
The promise of gene editing is moving closer to being a reality. If you're an investor with a speculative appetite and appropriate risk tolerance, you may want to consider a long position in gene edi
Editas Medicine, Inc. (EDIT) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
12:43am, Wednesday, 10'th Jan 2024
Editas Medicine, Inc. (EDIT) Presents at J.P. Morgan 42nd Annual Healthcare Conference (Transcript)
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
07:45am, Monday, 08'th Jan 2024
Intellia Therapeutics and Editas Medicine are pre-revenue biotechs. Editas is a long way from commercializing its first medicine.
Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why
11:16am, Tuesday, 02'nd Jan 2024
Editas (EDIT) shares have gained 23% in the past six months, driven by encouraging findings from the EDIT-301 studies in SCD and TDT, along with a licensing deal for its CAS9 gene-editing tool with Ve
2 gene-editing stocks reshaping hereditary disease treatments
07:16am, Tuesday, 02'nd Jan 2024
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a sickle
Editas Just Caught a Break Thanks to Vertex Pharmaceuticals
08:02am, Saturday, 23'rd Dec 2023
Vertex Pharmaceuticals will pay Editas Medicine to license its Cas-9 gene-editing technology. Editas can still license the same technology to other companies.
Editas (EDIT) Licenses Cas9 Tool to Vertex, Stock Up 6%
09:46am, Thursday, 14'th Dec 2023
Editas (EDIT) stock rises 6% on a non-exclusive agreement with Vertex Pharmaceuticals to license its Cas9 gene-editing technology for the development of the latter's gene therapy drug, Casgevy.
Vertias's $100M deal to license Editas IP sets a precedent for gene-editing therapy developers in the US
06:56pm, Wednesday, 13'th Dec 2023
Vertex Pharmaceuticals (NASDAQ:VRTX) shares surged more than 13% to a record higher Wednesday after the company announced an agreement to license CRISPR-Cas9 gene-editing technology from Editas Medici
Vertex's stock heads for all-time high as non-opioid painkiller shows promise
12:03pm, Wednesday, 13'th Dec 2023
Vertex Pharmaceuticals Inc. shares VRTX, +10.68% were on track for an all-time high Wednesday after the company released new data from a trial of its investigational non-opioid pain medicine.
3 Biotechs With Promising Gene Therapies in the Spotlight
09:47am, Wednesday, 13'th Dec 2023
The recent FDA approval of two gene therapies has put the focus on biotechs like EDIT, BEAM and NTLA, which have promising candidates in their pipeline.
Editas Medicine, Inc. (EDIT) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update (Transcript)
05:50pm, Monday, 11'th Dec 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) EDIT-301 Program Update: RUBY and EdiTHAL Trials Data Update December 11, 2023 1:00 PM ET Company Participants Cristi Barnett - Corporate Communications & IR Gilmo
1 Promising Stock Down 66% That Could Skyrocket in 2024
07:00am, Tuesday, 05'th Dec 2023
Editas Medicine is developing a promising gene-editing therapy. The biotech has several data readouts planned for the next 12 months.
Hidden Gems: 2 undiscovered stocks set to soar in 2024
10:21am, Thursday, 30'th Nov 2023
The stock market is full of surprises that can be lucrative for investors, especially for those who can recognize early on the potential that can bring returns that are multiple times larger than the
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
02:28pm, Wednesday, 29'th Nov 2023
Some of the hottest opportunities can be found in biotech stocks. Look at gene editing companies, like CRISPR Therapeutics (NASDAQ: CRSP ), for example.
